synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-07. Anything still debated is marked as such rather than presented as settled.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
| Property | Value | Notes |
|---|---|---|
| 化学分类 | 线性肽 | 由28个氨基酸组成 |
| 分子量 | 约3108 Da | 合成版本一致 |
| 外观 | 白色至类白色粉末 | 冻干品 |
| 溶解度 | 易溶于水 | 微溶于有机溶剂 |
| 储存温度 | -20°C（冻干） | 溶解后2-8°C |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
=== Translation === fMet is required for efficient initiation of protein synthesis in most groups of bacteria. The 30S ribosome–mRNA complex specifically recruits tRNAs with a formylated amino acid – tRNAfMet attached to fMet in the natural case. Because the fMet directs initiation, proteins in bacteria start (N-terminus) with a fMet residue instead of a methionine. Further occurrences of the "AUG" codon will result in a normal methionine, because a normal "elongating" tRNAMet is used. The addition of the formyl group to methionine is catalyzed by the enzyme methionyl-tRNA formyltransferase. This modification is done after methionine has been loaded onto tRNAfMet by aminoacyl-tRNA synthetase. Methionine itself can be loaded either onto tRNAfMet or tRNAMet. However, formyltransferase will catalyze the addition of the formyl group to methionine only if methionine has been loaded onto tRNAfMet, not onto tRNAMet. This is because the formyltransferase recognizes specific features of tRNAfMet. The mitochondria of eukaryotic cells, including those of humans, and the chloroplasts of plant cells also initiate protein synthesis with fMet. Given that mitochondria and chloroplasts have this initial protein synthesis with fMet in common with bacteria, this has been cited as evidence for the endosymbiotic theory. Unexpectedly, formyltransferase can also act upon eukaryotic initiator tRNA in living yeast cells. Even under normal conditions, the nuclear-encoded formyltransferase is not completely imported into mitochondria; even more is left in the cytosol under stress.
=== MMPs regulation === Under physiological conditions, MMPs are regulated at five levels: transcription; activation of zymogen precursors; interaction with ECM components; inhibition by TIMPs; and regulated absorption/elimination of active proteases from the extracellular environment. The majority of the literature is based on an investigation of transcriptional level (level 1) modifications, which lacks information on the physiologically relevant actions and control of secreted and post-translationally activated proteases. Future study could focus on the post-transcriptional regulation of MMP activity, especially in vivo.
Central nervous system: fatigue, dizziness, drowsiness, lightheadedness, confusion, nightmares, agitation, increased anxiety, difficulty sleeping, seizures (infrequently), temporary confusion (delirium), rarely induction of hypomania and psychosis, extrapyramidal side effects (rarely), abuse in patients with polytoxicomania (rarely), ringing in the ears (tinnitus) Anticholinergic: dry mouth, constipation, even ileus (rarely), difficulties in urinating, sweating, precipitation of glaucoma Antiadrenergic: Low blood pressure, (if patient arises too fast from the lying/sitting position to standing—known as orthostatic hypotension), abnormal heart rhythms (e.g., sinus tachycardia, bradycardia, and atrioventricular block) Allergic/toxic: skin rash, photosensitivity, liver damage of the cholestatic type (rarely), hepatitis (extremely rare), leuko- or thrombocytopenia (rarely), agranulocytosis (very rarely), hypoplastic anemia (rarely) Others: frequently increased appetite and weight gain, rarely nausea, rarely high blood pressure. May increase or decrease liver enzyme levels in the blood of some people. The side effects of low-dose doxepin for insomnia in long-term clinical trials (28 to 85 days) in adults and elderly people were as follows:
16 December – The UK government orders an independent review into foreign financial interference in UK politics in response to the case of Nathan Gill, the former leader of Reform UK in Wales. The Employment Rights Bill passes its final vote in the House of Lords and will receive Royal ascent before Christmas. It is announced that former Chancellor George Osborne is to join OpenAI. 17 December – Labour grants six local authorities in and around London the power to raise larger council tax increases after reducing their share of government funding. Starmer urges Russian oligarch Roman Abramovich to honour the pledge he made to donate the £2.5bn he made from the sale of Chelsea F.C. in 2022 to victims of the Ukraine War or he will face legal proceedings. Andrea Egan is elected as general secretary of Unison, and will succeed Christina McAnea in January. Former Labour mayor Jamie Driscoll joins the Green Party. Independent MP Zarah Sultana begins a protest outside HMP Bronzefield in Surrey, where remand prisoner, who had spent over a year in prison awaiting trial, and Palestine Action member Qesser Zuhrah is on hunger strike. The protest demanded an ambulance be brought to the prison, where Zuhrar has been on hunger strike for 46 days. She was later transferred to hospital. 18 December – Christian Turner is named as the UK's new ambassador to the United States, replacing Peter Mandelson. It is announced that Nigel Farage will not face an investigation into claims Reform overspent during his 2024 election campaign.
There are debates over other potential causes such as nighttime drops in blood pressure, as well as the hypothesis that the optic disc's ability to regulate its blood flow may be compromised. Some researchers have even suggested that blockages in the veins could be responsible. One hypothesis suggests that the underlying cause may be a subtle decrease in blood flow to the optic nerve, which is enough to cause swelling of the nerve fibers but not severe enough to disrupt vision through tissue death and permanent damage to the optic nerve. When considering the possible causes for spontaneous NAION, the list includes other conditions like arteritic anterior ischemic optic neuropathy (associated with inflammation of arteries), optic neuritis (inflammation of the optic nerve), infiltrative and compressive types of optic neuropathy (where the optic nerve is invaded or pressed upon by abnormal substances or structures), diabetic papillopathy (swelling of the optic disc in diabetes), radiation-induced damage to the optic nerve, neuroretinitis (inflammation of the optic nerve and retina), and swelling of the optic disc linked with retinal diseases like central retinal vein occlusion.
Sources: en.wikipedia.org
According to some studies, "the most effective sunscreens contain avobenzone and titanium dioxide." Avobenzone can degrade faster in light in combination with mineral UV absorbers like zinc oxide and titanium dioxide, though with the right coating of the mineral particles this reaction can be reduced. A manganese doped titanium dioxide may be better than undoped titanium dioxide to improve avobenzone's stability.
=== Parenteral === The term parenteral is from para-1 'beside' + Greek enteron 'intestine' + -al. This name is due to the fact that it encompasses a route of administration that is not intestinal. However, in common English the term has mostly been used to describe the four most well-known routes of injection.
=== Pivot to scientific instruments === HVEC had originally built products for clients in cancer therapy and industrial radiography, but its machines proved valuable for basic research. The company's proximity to MIT research gave it unique advantages in understanding accelerator requirements. Van de Graaff, Trump, and fellow board member William Buechner regularly consulted with physicists pushing the boundaries of nuclear structure studies, translating experimental needs into engineering specifications. In 1949, Brookhaven National Laboratory commissioned HVEC to build a 4 MeV Van de Graaff particle injector for its planned high-energy Cosmotron accelerator. When completed in 1953, the Cosmotron became the first accelerator to exceed billion-electronvolt potentials. HVEC's standard 2 MV accelerators also found nuclear science customers, including the Naval Research Laboratory and European universities. In 1951, HVEC adopted a Trump-designed MIT accelerator as a research accelerator prototype. This single-stage "CN" model was the first mass-produced research accelerator. CN machines operated at voltages up to 6.5 megavolts and established HVEC's reputation for reliability in nuclear research applications. In 1954, Canada's Chalk River Laboratories asked HVEC to modify the CN into higher-voltage tandem accelerator, yielding a highly profitable product line that sustained the company for fifteen years.
are not two constants but some random variables (a pair for each individual). This procedure has several names : "heterogeneous model", "structuration" (see also below for age structured models) or "Bayesian" view. Surprising results emerge, for instance it was proved in that the number of infected at the peak of a heterogeneous epidemic is smaller than the deterministic epidemic having same average
Sources: en.wikipedia.org
Algaecide or algicide is a biocide used for killing and preventing the growth of algae, often defined in a loose sense that, beyond the biological definition, also includes cyanobacteria ("blue-green algae"). An algaecide may be used for controlled bodies of water (reservoirs, golf ponds, swimming pools), but may also be used on land for locations such as turfgrass.
== Other uses == The ground product can be called masa nixtamalera. In Central American and Mexican cuisine, masa nixtamalera is cooked with water and milk to make a thick, gruel-like beverage called atole. When made with chocolate and sugar, it becomes atole de chocolate. Adding anise and piloncillo to this mixture creates champurrado, a popular breakfast drink.
Neural connections are constantly changing within the nervous system. Synaptic connections that are used more often are kept intact and promoted, while synaptic connections that are rarely used are subject to degradation. Elevated levels of synaptic connection loss and degradation of neurons are linked to neurodegenerative diseases. More recently, ferroptosis has been linked to diverse brain diseases, in particular, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. Two new studies show that ferroptosis contributes to neuronal death after intracerebral hemorrhage. Neurons that are degraded through ferroptosis release lipid metabolites from inside the cell body. The lipid metabolites are harmful to surrounding neurons, causing inflammation in the brain. Inflammation is a pathological feature of Alzheimer's disease and intracerebral hemorrhage. Recent studies have suggested that ferroptosis contributes to neuronal cell death after traumatic brain injury. Hypoxic brain injury in resuscitated patients shows retrospective evidence of ferroptosis. Additionally there is evidence that the prion protein and pathogenic prions PrPSc contribute to ferroptosis sensitivity in the brain, a condition that is enhanced by RAC3 expression.
Sources: en.wikipedia.org
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。
天然胸腺素α1主要从胸腺组织提取，也可在脾脏和淋巴结中检出。目前研究和临床使用的多为化学合成版本，不再依赖动物组织。
胸腺素组分5是牛胸腺提取物的粗组分，包含多种肽。胸腺素α1是其中一种被纯化和表征的单一肽，具有明确的28个氨基酸序列。
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.